Market Cap 383.99M
Revenue (ttm) 292.50M
Net Income (ttm) -33.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.62%
Debt to Equity Ratio 0.00
Volume 483,200
Avg Vol 634,786
Day's Range N/A - N/A
Shares Out 40.63M
Stochastic %K 89%
Beta 0.67
Analysts Strong Sell
Price Target $18.25

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 518 795 1400
Address:
14 Plaza Drive, Latham, United States
ReversalTracker
ReversalTracker Aug. 23 at 5:39 AM
$ANGO AngioDynamics is a medical device company facing product recalls and restructuring challenges
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 6:08 PM
$ANGO's resilience amidst industry decline — what's driving the optimism? 🚀 🌟 Solid performance in Q4 FY2025 with revenues surpassing expectations 🩺 NanoKnife's ongoing FDA clearance & clinical progress underpin growth 📈 AngioDynamics projects 50% growth over the next year in its business Discover the full potential here 👉 https://www.zacks.com/stock/news/2741129/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2741129-body-8926&ADID=SYND_STOCKTWITS_TWEET_2_2741129_BODY_8926
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 5:08 PM
$ANGO — Hidden strength in the face of headwinds? NanoKnife momentum, clinical milestones, and a well-balanced portfolio are giving this stock staying power, even with tariff pressures in the mix. See why ANGO still deserves a spot in your portfolio 👉 https://www.zacks.com/stock/news/2741129/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2741129-teaser-8924&ADID=SYND_STOCKTWITS_TWEET_2_2741129_TEASER_8924
0 · Reply
joketrader
joketrader Aug. 13 at 4:51 PM
$ANGO 👀 💪🏽
0 · Reply
joketrader
joketrader Aug. 6 at 7:33 PM
$ANGO 😂
0 · Reply
joketrader
joketrader Aug. 5 at 3:17 PM
$ANGO this low float is going to blow any day now
0 · Reply
joketrader
joketrader Aug. 5 at 2:11 PM
$ANGO 👀 💪🏽
0 · Reply
joketrader
joketrader Jul. 30 at 9:26 PM
$ANGO #tomorrow
0 · Reply
joketrader
joketrader Jul. 29 at 6:14 PM
$ANGO Im swinging this
0 · Reply
joketrader
joketrader Jul. 29 at 6:13 PM
$ANGO in for a swing 🤷🏽‍♂️
0 · Reply
Latest News on ANGO
AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 12:40 PM EDT - 5 weeks ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript


AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 10:20 AM EDT - 5 months ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript


AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 31, 2025, 8:00 AM EDT - 5 months ago

AngioDynamics to Host Virtual Cardiovascular Investor Event


AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 5:15 PM EST - 8 months ago

AngioDynamics: A Surgical Approach To Market Growth


AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 11:00 AM EST - 8 months ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript


AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Oct 3, 2024, 10:29 AM EDT - 11 months ago

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript


AngioDynamics to Participate in Upcoming Investor Conferences

Jul 29, 2024, 4:15 PM EDT - 1 year ago

AngioDynamics to Participate in Upcoming Investor Conferences


AngioDynamics: Lumpy Progress Is Still Progress

Jul 17, 2024, 3:16 PM EDT - 1 year ago

AngioDynamics: Lumpy Progress Is Still Progress


AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

Jul 16, 2024, 10:35 AM EDT - 1 year ago

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript


A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 9, 2024, 4:49 PM EDT - 1 year ago

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story


AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

Apr 4, 2024, 11:11 AM EDT - 1 year ago

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript


ReversalTracker
ReversalTracker Aug. 23 at 5:39 AM
$ANGO AngioDynamics is a medical device company facing product recalls and restructuring challenges
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 6:08 PM
$ANGO's resilience amidst industry decline — what's driving the optimism? 🚀 🌟 Solid performance in Q4 FY2025 with revenues surpassing expectations 🩺 NanoKnife's ongoing FDA clearance & clinical progress underpin growth 📈 AngioDynamics projects 50% growth over the next year in its business Discover the full potential here 👉 https://www.zacks.com/stock/news/2741129/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2741129-body-8926&ADID=SYND_STOCKTWITS_TWEET_2_2741129_BODY_8926
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 5:08 PM
$ANGO — Hidden strength in the face of headwinds? NanoKnife momentum, clinical milestones, and a well-balanced portfolio are giving this stock staying power, even with tariff pressures in the mix. See why ANGO still deserves a spot in your portfolio 👉 https://www.zacks.com/stock/news/2741129/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2741129-teaser-8924&ADID=SYND_STOCKTWITS_TWEET_2_2741129_TEASER_8924
0 · Reply
joketrader
joketrader Aug. 13 at 4:51 PM
$ANGO 👀 💪🏽
0 · Reply
joketrader
joketrader Aug. 6 at 7:33 PM
$ANGO 😂
0 · Reply
joketrader
joketrader Aug. 5 at 3:17 PM
$ANGO this low float is going to blow any day now
0 · Reply
joketrader
joketrader Aug. 5 at 2:11 PM
$ANGO 👀 💪🏽
0 · Reply
joketrader
joketrader Jul. 30 at 9:26 PM
$ANGO #tomorrow
0 · Reply
joketrader
joketrader Jul. 29 at 6:14 PM
$ANGO Im swinging this
0 · Reply
joketrader
joketrader Jul. 29 at 6:13 PM
$ANGO in for a swing 🤷🏽‍♂️
0 · Reply
joketrader
joketrader Jul. 29 at 6:11 PM
$ANGO 👀 💪
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 23 at 7:26 AM
$ANGO Outstanding article that hits the mark on ANGO's current state. So if you want to refresh your ANGO insights or learn about ANGO from scratch, this is a must read. https://beyondspx.com/article/angiodynamics-unlocking-medtech-growth-through-precision-and-strategic-focus-nasdaq-ango
0 · Reply
BioGem
BioGem Jul. 19 at 11:05 AM
$ANGO I added sub $9. Many positives: -Excellent beat on top and bottom lines. Yes, the guidance for 2026 is average, but management has always been conservative as they progressively beat and raise. -Undervalued based on DCF and multiples. -All analysts kept or raised price targets up to $24. -High quality Execs and BOD. -High CEO ownership of stock: 7x base salary. -Re-structuring of Co since 2024 was achieved smoothly with strong balance sheet, all debt paid off. -Steady growth, high quality products and Nanoknife approved with inflection point. -Profits in sight and free cash flow positive. -Stock buy backs ++. $IBB $XBI
0 · Reply
d_risk
d_risk Jul. 19 at 12:56 AM
$ANGO - AngioDynamics Inc. Common Stock - 10K - Updated Risk Factors ANGO’s 2025 risk factors pivot to market acceptance and reimbursement challenges, supply chain risks from trade tensions and partial outsourcing, intensified legal and regulatory scrutiny, restructuring impacts, worsening international sales decline, inflation and interest rate pressures, and ongoing EU regulatory hurdles; labor shortage and financing risks removed. #MedicalDevices #RegulatoryScrutiny #SupplyChainRisks #ReimbursementChallenges #MarketAcceptance 🟢 Added 🟠 Removed https://d-risk.ai/ANGO/10-K/2025-07-18
0 · Reply
Ka1ch123
Ka1ch123 Jul. 17 at 7:44 AM
$ANGO in @ 8.60. another runner?!
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 6:49 PM
Lake Street has updated their rating for AngioDynamics ( $ANGO ) to Buy with a price target of 24.
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 5:56 PM
$ANGO posts a narrower Q4 loss — but what's driving the optimism? 📈 ✔️ Adjusted loss per share beat estimates, trimming from last year ✔️ Revenues surged 12.9% in Q4, topping expectations ✔️ Strong Med Tech & Med Device performance led by Auryon and NanoKnife Discover the full earnings details here 👉 https://www.zacks.com/stock/news/2586115/ango-stock-down-despite-q4-earnings-beat-gross-margin-declines?cid=sm-stocktwits-2-2586115-body-2186&ADID=SYND_STOCKTWITS_TWEET_2_2586115_BODY_2186
0 · Reply
drmha
drmha Jul. 16 at 5:25 PM
$ANGO the average price target is 16 I am very a ware if the company product portfolio One of its product the competitor is inari who was acquired by a deal equl 5 billion dollar This is for one product of ango only the competitor market cap. I am very confident-this company portfolio at least give her the value if 3- 5 billion dollar Its for me institutions manipulation
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 4:15 PM
$ANGO beat Q4 — so why is the stock dropping? Strong Med Tech growth drove the earnings beat, but declining gross margins and a wider fiscal 2026 loss outlook are weighing heavy. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2586115/ango-stock-down-despite-q4-earnings-beat-gross-margin-declines?cid=sm-stocktwits-2-2586115-teaser-2144&ADID=SYND_STOCKTWITS_TWEET_2_2586115_TEASER_2144
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 1:12 PM
HC Wainwright & Co. updates rating for AngioDynamics ( $ANGO ) to Buy, target set at 16.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 12:00 PM
Canaccord Genuity has adjusted their stance on AngioDynamics ( $ANGO ), setting the rating to Buy with a target price of 15 → 17.
0 · Reply
theflynews
theflynews Jul. 15 at 8:24 PM
What You Missed On Wall Street On Tuesday - $ANGO - https://thefly.com/permalinks/entry.php/ANGOid4159991?1752610920C38
0 · Reply